Scholar Rock (NASDAQ:SRRK) removed Catalent Indiana as a commercial fill-finish facility from its apitegromab Biologics License Application (BLA) for spinal muscular atrophy (SMA), with FDA review continuing using an alternate facility.
Yatra Online (NASDAQ:YTRA) confirmed that Magna Holdings launched an unsolicited tender offer to purchase up to 20 million ordinary shares of Yatra at $1.10 per share in cash.
Alvotech (NASDAQ:ALVO) entered a strategic licensing and commercialization agreement with Lotus Pharmaceutical covering two biosimilar candidates, AVT34 and AVT87, with potential value of approximately $150 million.
Broadcom is in talks to raise more than $60 billion in debt for an AI chip financing deal that will benefit Anthropic PBC and other companies. Ed Ludlow reports on Bloomberg Television.
Treasury Secretary Scott Bessent vowed to ramp up pressure on Iran by targeting its economic partners, saying "You are either with us, or against us." He is scheduled to talk more about the plans on Monday. Bloomberg's Tyler Kendall reports.
Molly Brooks, US rates strategist at TD Securities, sees the potential for an "asymmetric risk" to markets from Federal Reserve Chairman Kevin Warsh's comments in Jackson Hole next week and explains what she sees driving the recent back up in long-end Treasuries.
FedEx (NYSE:FDX) declared a quarterly cash dividend of $1.22 per share on common stock, payable on October 1, 2026, to shareholders of record as of September 14, 2026.
Vivakor (NASDAQ:VIVK) reported second-quarter 2026 revenue of $32.1 million, up 10% year over year, as expanded crude oil Supply & Trading activities supported growth.
reAlpha Tech Corp (NASDAQ:AIRE) completed its acquisition of InstaMortgage on August 19, 2026, adding direct mortgage lending capabilities to its real estate technology platform.
Milestone Pharmaceuticals (NASDAQ:MIST) enrolled the first patient in ReVeRA-301, a pivotal Phase 3 trial evaluating etripamil nasal spray for atrial fibrillation with rapid ventricular rate (AFib-RVR).
Werewolf Therapeutics (NASDAQ:HOWL) and Ambros Therapeutics entered an all-stock merger agreement that will create a Nasdaq-listed biotechnology company focused on developing neridronate for Complex Regional Pain Syndrome Type 1 (CRPS-1).
Permian Basin Royalty Trust (NYSE:PBT) declared an August 2026 cash distribution of $871,663.17, or $0.018701 per unit, based on production from its underlying royalty properties.
